News Releases
Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
Sep 16, 2026
Regeneus trebles on back of merger deal (Sydney Morning Herald)
Apr 5, 2024
Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease
Feb 6, 2024
Back to Investors and Media
Our Pipeline
Our Science
Investors and Media
About Us
Contact Us
Our Pipeline
Our Science
Investors and Media
About Us
Contact Us